aarti drugs

Aarti – 5x in 2.5 years…Coverage closure update

February 19, 2021

Dear Sir, In Sep’18 we initiated coverage on Aarti, leading API manufacturer, for our Premium Members. You can read the detailed initiation report on the company at the following LINK Recently, on 5th Feb’21, we finally closed the coverage on the stock and booked complete profit in our Model Sheets as well. The company has been a great wealth creator for us and our members. We first initiated coverage on the same in Feb’14 around 27-28 odd levels (adjusted for…

Read More

How to Identify Stocks with Low Downside Risk and Potential for Large Gains?…Backed with Examples

October 15, 2020

Dear Sir, Hope you are doing well. Today, I would like to share with you our thought process on how to identify stocks with low downside risk and potential for high pay offs. I think you will agree with the following two facts: All the businesses are cyclical to varying extents and go through lean periods, and Best returns are generated when a company goes through both Earnings and PE expansion Thus, if you combine the two, we get the…

Read More

Aarti Drugs – 500% + Return in the last few months…Is it time to be Cautious?

August 31, 2020

Dear Sir, Hope you are doing well. It’s always to great to have stocks that end up multiplying your wealth several times; however, during one’s holding of such stocks there also comes a time when one needs to get cautious and have some profit protection strategy in place. Here, we are talking about Aarti Drugs. The stock has been a great wealth creator for our Premium Members as we could identify the stock at levels of 550 in Sep’18 and since…

Read More

7th Aug’20 – Jun’20 earnings update on Manappuram and Aarti Drugs

August 7, 2020

Dear Members, We have released 7th Aug’20 – Jun’20 earnings update on Manappuram Finance and Aarti Drugs. The same has been produced below. For other updates, please refer the following link – https://katalystwealth.com/category/latest-updates/ Date: 7th Aug’20   Manappuram Finance (NSE – MANAPPURAM) – Jul’17 Alpha stock CMP – 161.60 (BSE); 161.60 (NSE) Rating – Positive – 8% weightage; this is not an investment advice (refer rating interpretation) Source: bseindia.com Manappuram has reported decent set of numbers for Q1 FY 21; however,…

Read More